Eli Lilly(NYSE:LLY) is navigating a dynamic environment marked by both opportunities and challenges. Recent highlights ...

The U.S. Food and Drug Administration has approved Eli Lilly's Ebglyss (lebrikizumab-lbkz) for adults and children aged 12 ...

Ebglyss is a new biologic treatment for moderate-to-severe eczema that isn’t controlled with topical therapies. The ...

The Food and Drug Administration (FDA) has approved Ebglyss™ (lebrikizumab-lbkz) for the treatment of adult and pediatric ...

Eli Lilly and Company has announced the FDA approval of EBGLYSS for treating atopic dermatitis in adults and children over 12 ...

The FDA has approved Lilly’s Ebglyss (lebrikizumab-lbkz) for the treatment of moderate to severe atopic dermatitis in adults ...

In the United States and some countries other than Europe, Lilly owns exclusive development and commercialization rights to ...

The FDA has approved Eli Lilly's Ebglyss for moderate-to-severe eczema in patients 12 and older. The treatment is ...

Three years after establishing an immunology unit, Eli Lilly has gained its third FDA approval in the specialty area as the U ...

With school back in session, Purdue University saw a record number of applicants. Wall Street analyst Jane King says Purdue ...